KLK3 and prostate cancer: Data from Australia, Canada, and some Western Europe countries suggest PSA screening is increasingly common with older age.16,20–22 NCDA data suggest asymptomatic prostate cancer diagnosis following PSA testing is less common compared with symptomatic detection in England as age increases, which may reflect the increasing incidence of LUTS with age rather than PSA test rates.